Micropos Medical (MPOS) Q1 2026 earnings summary

Executive summary

• Net sales for the period were 485 Tkr, a significant decrease from 2,631 Tkr year-over-year.

• Result after financial items was -6,945 Tkr compared to -5,516 Tkr in the same quarter last year.

• Equity at period end was 6,773 Tkr, down from 29,728 Tkr year-over-year.

• Over 400 patients have now been treated with ASBRT and Raypilot System, with growing clinical acceptance and market interest.

• MDR certification was achieved, enabling resumed product development and supply chain changes.

Financial highlights

• Operating result for the group was -7,055 Tkr, compared to -5,330 Tkr year-over-year.

• Cash flow from operations was -6,754 Tkr, with cash and cash equivalents at 3,076 Tkr at period end.

• Equity ratio decreased to 59% from 81% year-over-year.

• Earnings per share remained at -0.04 kr, unchanged from the previous year.

• Number of outstanding shares increased to 166,499,280 from 152,624,340.

Outlook and guidance

• Focus remains on increasing the number of treated patients at both existing and new customer sites.

• Future prospects are positive, assuming SBRT becomes standard treatment, but liquidity remains a challenge due to slow patient ramp-up.

• A new share issue was announced after the period to raise over 24 Mkr for marketing and sales in Europe and the US.